肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

甲状腺癌治疗的新思路：将肿瘤抑制基因传递给癌细胞

2020-01-30 Allan MedSci原创

甲状腺癌肿瘤抑制基因TUSC2
关注

Genprex是一家临床阶段的基因治疗公司，该公司利用独特的、非病毒性的专有平台将肿瘤抑制基因传递给癌细胞，今日宣布，由独立研究人员完成的一项研究显示，TUSC2是一种抑癌基因，是甲状腺癌的潜在靶标和生物标志物。TUSC2也是Genprex的Oncoprex™免疫基因治疗中的活性剂。

Genprex是一家临床阶段的基因治疗公司，该公司利用独特的、非病毒性的专有平台将肿瘤抑制基因传递给癌细胞，今日宣布，由独立研究人员完成的一项研究显示，TUSC2是一种抑癌基因，是甲状腺癌的潜在靶标和生物标志物。TUSC2也是Genprex的Oncoprex™免疫基因治疗中的活性剂。

该研究发表在《International Journal of Molecular Sciences》上，该研究称TUSC2过表达减少了甲状腺癌的增殖、迁移和侵袭。TUSC2过度表达减少了甲状腺癌细胞的增殖，可能代表了阻止癌细胞增殖的重要工具。研究还发现，TUSC2通过增加SMAC / DIABLO和细胞色素C蛋白来增加对细胞凋亡的敏感性。TUSC2的过度表达增加了这些蛋白质的水平，相反，TUSC2的基因沉默诱导了肿瘤细胞对细胞凋亡的抵抗力。


原始出处：

https://www.firstwordpharma.com/node/1696967?tsid=4

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1706068, encodeId=130f1e0606887, content=<a href='/topic/show?id=d7d55492301' target=_blank style='color:#2F92EE;'>#抑制基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54923, encryptionId=d7d55492301, topicName=抑制基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=964031147987, createdName=xiay994463, createdTime=Thu Nov 19 06:23:00 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809166, encodeId=c63618091667b, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 10 04:23:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019360, encodeId=d08b2019360e8, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Wed Jun 10 17:23:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252671, encodeId=547512526e160, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Feb 01 12:23:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-11-19 xiay994463

    #抑制基因#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1706068, encodeId=130f1e0606887, content=<a href='/topic/show?id=d7d55492301' target=_blank style='color:#2F92EE;'>#抑制基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54923, encryptionId=d7d55492301, topicName=抑制基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=964031147987, createdName=xiay994463, createdTime=Thu Nov 19 06:23:00 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809166, encodeId=c63618091667b, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 10 04:23:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019360, encodeId=d08b2019360e8, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Wed Jun 10 17:23:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252671, encodeId=547512526e160, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Feb 01 12:23:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-05-10 tsing_hit

    #肿瘤抑制#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1706068, encodeId=130f1e0606887, content=<a href='/topic/show?id=d7d55492301' target=_blank style='color:#2F92EE;'>#抑制基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54923, encryptionId=d7d55492301, topicName=抑制基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=964031147987, createdName=xiay994463, createdTime=Thu Nov 19 06:23:00 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809166, encodeId=c63618091667b, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 10 04:23:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019360, encodeId=d08b2019360e8, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Wed Jun 10 17:23:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252671, encodeId=547512526e160, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Feb 01 12:23:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-06-10 晓辰

    #新思路#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1706068, encodeId=130f1e0606887, content=<a href='/topic/show?id=d7d55492301' target=_blank style='color:#2F92EE;'>#抑制基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54923, encryptionId=d7d55492301, topicName=抑制基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=964031147987, createdName=xiay994463, createdTime=Thu Nov 19 06:23:00 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809166, encodeId=c63618091667b, content=<a href='/topic/show?id=a68f829380b' target=_blank style='color:#2F92EE;'>#肿瘤抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82938, encryptionId=a68f829380b, topicName=肿瘤抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dcaa509, createdName=tsing_hit, createdTime=Sun May 10 04:23:00 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019360, encodeId=d08b2019360e8, content=<a href='/topic/show?id=61f458359f7' target=_blank style='color:#2F92EE;'>#新思路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58359, encryptionId=61f458359f7, topicName=新思路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Wed Jun 10 17:23:00 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252671, encodeId=547512526e160, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Sat Feb 01 12:23:00 CST 2020, time=2020-02-01, status=1, ipAttribution=)]
    2020-02-01 yxch36

    #癌细胞#

    0

相关资讯

Clin Endocrinol：肥胖对甲状腺癌风险的影响因年龄而异

目前，肥胖与分化型甲状腺癌（DTC）之间的关系仍存争议。有些研究显示，两者呈正相关；但也有研究显示两者之间并无显著关系。此外，既往有关肥胖与DTC关系的研究主要是在西方人群中进行，而亚洲人群的相关研究证据较少。近期在Clinical Endocrinology杂志上发表的一项最新研究为我们带来了中国人群中肥胖与DTC相关的新数据。其结果显示，与无甲状腺疾病的对照者相比，中国成年DTC患者更多伴有超

2019 ESMO临床实践指南：甲状腺癌的诊断，治疗和随访

2019年9月，欧洲肿瘤内科学会(ESMO)发布了甲状腺癌的诊断，治疗和随访指南，文章主要目的是为临床医生提供关于特定问题的最佳证据和实用建议。内容涉及甲状腺癌的诊断，治疗以及随访。

精准诊疗时代，甲状腺癌靶向治疗即将迎来“自主”时代

作为最常见的内分泌恶性肿瘤，甲状腺癌的发病率在近年呈现显着上升的趋势。甲状腺癌可以分为多种亚型，其中分化型甲状腺癌（DTC）占所有甲状腺癌的90% ~ 95%，通常情况下DTC生长缓慢，传统手术治疗患者的20年生存率超过90%。但仍有部分患者会出现肿瘤复发、转移，且对放射性碘治疗无效，其10年生存率较低。而另一种甲状腺癌的亚型——甲状腺髓样癌（MTC）更是预后差，早期易发生转移。分享甲状腺癌诊疗难

高明教授：RET高选择性抑制剂Selpercatinib(LOXO-292)给甲状腺癌患者带来新希望

甲状腺癌是最为常见的内分泌恶性肿瘤，近年来发病率逐年上升。根据肿瘤起源及分化差异，甲状腺癌可以分为多种亚型，包括甲状腺乳头状癌、甲状腺滤泡癌、甲状腺髓样癌以及甲状腺未分化癌等。其中甲状腺髓样癌约占甲状腺癌的2%~4%，病变来源于甲状腺滤泡旁细胞，是预后较差，早期易发生转移的亚型。

2019 专家共识：乐伐替尼治疗甲状腺癌期间不良事件的管理

乐伐替尼是一种口服多激酶抑制剂，经批准用于治疗侵袭性、局部进展或转移、放射碘不敏感的分化型甲状腺癌。本文主要针对乐伐替尼治疗甲状腺癌期间不良事件的管理提供共识指导。

NCCN临床实践指南：甲状腺癌（2019.V2）

2019年9月，美国国家综合癌症网络(NCCN)发布了甲状腺癌指南2019年第2版，指南更新摘要如下： 甲状腺癌 结节评估 TSH抑制原理 激酶抑制剂治疗晚期甲状腺癌的原则 乳头状瘤 FNA结果,诊断程序,术前或术中决策标准,初级治疗 滤泡性癌 FNA结果,诊断程序，初级治疗 许特尔细胞癌 FNA结果,诊断程序，初级治疗 甲状腺髓样癌 临床表现，诊断程序，初级治疗 生殖系RET原癌基因的突变 未分